Skip to main content

Table 2 Postoperative adjuvant immunotherapy trials for HCC

From: Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma

Identifier No.

Interventions

Setting

Primary outcome

NCT03859128 (JUPITER 04)

Toripalimab or placebo

Phase 2, 3

RFS

NCT03383458 (CheckMate 9DX)

Nivolumab or placebo

Phase 3

RFS

NCT03867084 (KEYNOTE-937)

Pembrolizumab

Phase 3, Double-blinded, Placebo controled

RFS, OS

NCT04639180

Camrelizumab plus Apatinib

  

NCT04102098 (IMbrave050)

Atezolizumab plus Bevacizumab

Phase 3, open label, two arms (versus active surveillence)

RFS

NCT03847428 (EMERALD-2)

Durvalumab plus bevacizumab or durvalumab monotherapy or placebo

Phase 3, randomized, double-blind, placebo-controlled

RFS

NCT04418401 (CISLD-8)

Donafenib plus any anti-PD-1 antibody

Phase 1

1-year RFS

NCT04233840

Nivolumab and Ropeginterferon alfa-2b

Phase I/II Open Label

RFS